Aztherapies Inc., of Boston, said it closed a $26.3 million series C preferred equity financing co-led by Spinnaker Capital and Cosine, with participation from new and existing investors, including Drads Capital, IBS Capital and Wexford Capital. The proceeds are expected to fund the completion of COGNITE, the company's fully enrolled pivotal phase III trial, which is investigating the safety and efficacy of lead candidate ALZT-OP1 in patients with early Alzheimer's disease, and is being conducted under an FDA special protocol assessment. The funds will also help advance AZT-101 into a phase II trial in patients with post-ischemic stroke cognitive impairment and into a phase I/IIa trial in amyotrophic lateral sclerosis.
Innate Pharma SA, of Marseille, France, said it priced its IPO on Nasdaq by way of a capital increase of 12.5 million new ordinary shares, consisting of a public offering of 8.04 million American depositary shares (ADSs), each representing one ordinary share, at $5.50 per ADS, and a concurrent private placement of 4.45 million ordinary shares, priced at €4.97 (US$5.53) each, in Europe (including in France) and other countries outside of the U.S. Together with the U.S. offering, the aggregate gross proceeds will amount to approximately $68.8 million. The company has granted the underwriters an option to purchase an additional 1.875 million ADSs. The company expects to use some of the net proceeds to help advance the clinical development of its lead product candidate, monalizumab, in collaboration with Cambridge, U.K.-based Astrazeneca plc, which is currently being evaluated for the treatment of patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck and in patients with advanced solid tumors.
Plexium Inc., of San Diego, said it has launched and closed a $28 million series A financing round led by DCVC Bio and The Column Group, with participation from M Ventures, CRV and Neotribe Ventures. The company's platform, Delphe, enables cell-based phenotypic screening of DNA-encoded libraries in nanoliter volumes. The proceeds will be used to further advance that technology platform and build a pipeline of small molecules that modulate E3 ligases to selectively enhance and degrade protein targets.
Versameb AG, of Basel, Switzerland, said it closed a CHF6.4 million (US$6.5 million) seed C financing round that will be used to expand its technology platform, Versagile, in multiple indications and advance the lead program toward clinical studies. The platform enables efficient development of functional mRNA molecules for customized protein expression and modification in various therapeutic indications.